A cholinesterase inhibitor polymorph, wherein specifically disclosed are a octahydroaminoacridine succinate polymorph, a corresponding crystal composition and pharmaceutical composition, and applications thereof. The compound octahydroaminoacridine succinate is used for screening and studying polymorphs, and the discovered polymorphs are appraised and evaluated; crystal forms having better physical and chemical properties are determined for subsequent development and study, and crystal forms having good stability and an excellent therapeutic effect are obtained.

A cholinesterase inhibitor polymorph, wherein specifically disclosed are a octahydroaminoacridine succinate polymorph, a corresponding crystal composition and pharmaceutical composition, and applications thereof. The compound octahydroaminoacridine succinate is used for screening and studying polymorphs, and the discovered polymorphs are appraised and evaluated; crystal forms having better physical and chemical properties are determined for subsequent development and study, and crystal forms having good stability and an excellent therapeutic effect are obtained.

The present application discloses a tetrastyrene-based compound, an application thereof, and an electronic device using the same. The tetrastyrene-based compound has a general structural formula as shown in the following Formula 1:

##STR00001##

The tetrastyrene-based compound includes an aromatic amine and a rigid tetrastyrene structure, wherein the aromatic amine can effectively improve the hole injection and transport performance, and the rigid tetrastyrene structure is conducive to the formation of evaporation materials of melting type.

The present application discloses a tetrastyrene-based compound, an application thereof, and an electronic device using the same. The tetrastyrene-based compound has a general structural formula as shown in the following Formula 1:

##STR00001##

The tetrastyrene-based compound includes an aromatic amine and a rigid tetrastyrene structure, wherein the aromatic amine can effectively improve the hole injection and transport performance, and the rigid tetrastyrene structure is conducive to the formation of evaporation materials of melting type.

Described herein are compounds that inhibits the membrane proximal external region (MPER) of a viral envelope (Env), as well as and compositions thereof. Further provided herein are methods for treating or preventing a viral infection comprises administering to a subject in need thereof an agent or compound that inhibits the MPER of a viral Env. In certain embodiments, the viral infection is an HIV infection.

The disclosure is directed to bisaminoquinolines and bisaminoacridines as autophagy inhibitors for treating cancer and other disease states and conditions.

The disclosure is directed to bisaminoquinolines and bisaminoacridines as autophagy inhibitors for treating cancer and other disease states and conditions.

Provided are a method for producing a peptide compound including a step of using a compound represented by Formula (1); a protective group-forming reagent including the compound; and the compound. At least one of R.sup.1 to R.sup.8 or Y.sup.2 has R.sup.A, R.sup.A represents an aliphatic hydrocarbon group or an organic group having an aliphatic hydrocarbon group, and the number of carbon atoms in at least one aliphatic hydrocarbon group is 12 or more. However, R.sup.A does not have a silyl group and a hydrocarbon group having a silyloxy structure.

##STR00001##

The disclosure relates to compounds that are, e.g., PAP Associated Domain Containing 5 (PAPD5) inhibitors and methods of use thereof.

The present technology relates to compounds that inhibit human Ly6K and homologs thereof. Also disclosed are methods of using such compounds to: inhibit activity of a Ly6K protein in a cell; decrease migration, colony formation, and/or proliferation of a cell; modulate expression of a gene in a cell, reduce suppression of the immune response to cancer in a subject, decrease tumorigenic growth of a cancer in a subject, and treat or prevent in a subject a disorder mediated by Ly6K protein.